CTRI/2010/091/001299已完成3 期
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Diagnosis of type 2 diabetes mellitus prior to informed consent
- •2. Male and female patients on a diet and exercise regimen who are pre treated with immediate release metformin or immediate release metformin plus sulfonylurea (see below for minimum doses). The treatment regimen has to be unchanged for 12 weeks prior to randomisation.
- •Minimum dose for metformin: greater than or equal to 1500 mg per day or maximum tolerated dose or maximum dose according to local label Minimum dose for sulfonylurea: greater than or equal to half of the maximal recommended dose or maximum tolerated dose or maximum dose according to local label
- •3. HbA1c of greater than or equal to 7.0 per cent and less than or equal to 11 per cent at Visit 1 (screening) in order to be eligible for randomised treatment HbA1c of greater than 11 per cent at Visit 1 (screening) in order to be eligible for the open-label treatment arm (25 mg BI 10773)
- •4. Age in between 18 and 65
- •5. Body Mass Index BMI less than or equal to 45 kg per meter square (Body Mass Index) at Visit 1 (Screening)
- •6. Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation
排除标准
- •1. Uncontrolled hyperglycaemia with a glucose level greater than 240 mg per dl (greater than 13.3 mmol per L) after an overnight fast during placebo run in and confirmed by a second measurement (not on the same day)
- •2. Any other antidiabetic drug within 12 weeks prior to randomisation except those mentioned in inclusion criterion 2
- •3. Myocardial infarction, stroke or transient ischemic attack (TIA) within 3 months prior to informed consent
- •4. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 times upper limit of normal (ULN) as determined during screening and/or run-in phase
- •5. Impaired renal function, defined as eGFR less than 30 ml per min (severe renal impairment) as determined during screening and/or run-in phase
- •6. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption
- •7. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years
- •8. Contraindications to metformin and/or sulfonylurea according to the local label for those patients that enter the study with the respective background therapy
- •9. Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anaemia)
- •10. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight
- •11. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except Typ 2 Diabetes
- •12. Pre-menopausal women (last menstruation 1 year prior to informed consent) who:
- •- are nursing or pregnant or
- •- are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence (if acceptable by local authorities), double barrier method and vasectomised partner
- •13. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake
- •14. Participation in another trial with an investigational drug within 30 days prior to informed consent
- •15. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial
研究者
相似试验
已完成
不适用
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent AsthmaPER-090-10Boehringer Ingelheim,22
已完成
3 期
A Phase III Randomised, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Tranexamic Acid in Reducing the Blood Loss in Patients with Per-rectal BleedingACTRN12611000865910John Hunter Hospital100
进行中（未招募）
1 期
Phase III Double-blind, Placebo-controlled Study of AZD1222 for thePrevention of COVID-19 in AdultsSARS-COV-2 infection (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005226-28-ITASTRAZENECA AB40,000
进行中（未招募）
1 期
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in AdultsSARS-COV-2 infection (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005226-28-FRAstraZeneca AB40,000
进行中（未招募）
1 期
Phase III, double-blinded study using AZD7442 or Placebo for the prevention of COVID-19 disease in adults who have been potentially exposed to COVID-19.EUCTR2020-004719-28-GBAstraZeneca AB1,125